menu
    • menu

    Company profile for Apnimed

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Apnimed was founded in 2017 and is located in Cambridge, MA. We are a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ApnimedUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    20 Holyoke Street, Cambridge, MA 02138
    Telephone
    Telephone
    (617) 500-8880
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://apnimed.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apnimed To Join Lifesci Capital & Sofinnova Partners Summit
    Apnimed To Join Lifesci Capital & Sofinnova Partners Summit

    10 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-to-participate-in-the-lifesci-capital--sofinnova-partners-growth-and-innovation-summit-302607744.html

    PR NEWSWIRE
    10 Nov 2025
    Share Share
    Apnimed Publishes Positive Phase 2 Results of OSA in Lancet
    Apnimed Publishes Positive Phase 2 Results of OSA in Lancet

    03 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-announces-publication-in-the-lancet-of-positive-phase-2-results-demonstrating-sulthiames-efficacy-in-obstructive-sleep-apnea-302602583.html

    PR NEWSWIRE
    03 Nov 2025
    Share Share
    Apnimed To Present Phase 3 Data For AD109, At CHEST 2025 Meeting
    Apnimed To Present Phase 3 Data For AD109, At CHEST 2025 Meeting

    17 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-to-present-additional-phase-3-data-for-ad109-an-investigational-oral-pill-for-obstructive-sleep-apnea-at-chest-2025-annual-meeting-302587042.html

    PR NEWSWIRE
    17 Oct 2025
    Share Share
    Apnimed Presents Positive AD109 Phase 3 Data At CHEST Meeting
    Apnimed Presents Positive AD109 Phase 3 Data At CHEST Meeting

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-announces-acceptance-of-two-late-breaking-presentations-and-a-core-interactive-session-at-the-chest-annual-meeting-highlighting-new-positive-ad109-phase-3-data-and-the-current-unmet-need-in-obstructive-sleep-apnea-302576420.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share
    Apnimed’s AD109 Shows Positive Results in 2nd Ph3 Sleep Trial
    Apnimed’s AD109 Shows Positive Results in 2nd Ph3 Sleep Trial

    23 Jul 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apnimed-reports-positive-topline-results-from-second-phase-3-trial-of-ad109-reinforcing-potential-of-first-oral-pill-for-obstructive-sleep-apnea-302511320.html

    PR NEWSWIRE
    23 Jul 2025
    Share Share
    Apnimed's Sleep Apnea Drug Succeeds in Phase 3 Trials
    Apnimed's Sleep Apnea Drug Succeeds in Phase 3 Trials

    23 Jul 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/apnimeds-sleep-apnea-asset-goes-two-two-ph-3-solidifying-star-potential

    FIERCE BIOTECH
    23 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search